NDA Group Releases Data Comparing FDA and EMA Ahead of Annual DIA Europe in Basel
January 20, 2018 – Other –
Today NDA Group announced their findings from its fifth annual comparison of drug approvals in Europe and the United States, in preparation for this yearís DIA Europe in Basel, Switzerland. The figures highlight the continued differences between the two regions, and the need for a global approach to drug development to ensure success across both continents.
This yearís report – based on preliminary research figures distilled from the EMA and FDA websites in January 2018 – found that once again, we see more approvals and also more novel drugs approved compared to 2016 yearís drop. For 2017 there were a total of 103 new drug approvals granted in the US and EU. Of these new products, 15 were approved only in the EU, 52 only in the US, and 36 were granted in both regions. 56 of the drugs were classified as novel drugs, 6 were approved only in the EU, 27 only in the US and 23 in both regions.
Johan Strˆmquist, CEO, NDA Group ‘We are pleased to see that the drug approvals are increasing again compared to 2016 yearís figures. Itís also interesting to see that for the first time since we started to analyse the drug approvals small and medium sized pharma are ahead of big pharma.’
‘Our analysis for 2017 shows that NDA maintains an exceptional position in supporting new drug product approvals in Europe. During the last five years NDA supported over 40% of the new drugs approved with a broad range of services. This is particularly exciting as an increasing proportion of products are emerging based on highly innovative and ground-breaking technologies. This is where we at NDA Group truly excels.’
Dr Terese Johansson, NDAís consultant behind the research commented:
‘The findings released today show some precedence setting new approvals. In the US the Keytruda, (pembrolizumab) approval in oncology demonstrates the shift from defining cancers by the site at which they occur toward a definition by the molecular changes that drives the tumorigenesis. This approval is likely to have implications for how the drug development process is pursued in the future, particularly in oncology, but most likely also for other therapeutic areas as science progresses. Looking at the therapeutic areas, the far busiest was oncology. With a total of 27 new oncology approvals, so far 12 of these are only approved in the US. Moreover, the first digital pill (Abilify MyCite, aripiprazole) has seen the light of day in US.’
Highlighted in the report released today are also some noteworthy Orphan approvals. With more treatments for orphan diseases hitting the market the pricing of these drugs becomes increasingly important. Terese Johansson continues: ‘Drug developers are meeting the treatment demand from the patients and physicians but are the payers willing to pay the price? Drug developers will benefit from being prepared early on to develop strategies to ensure patient access and affordability of their orphan drugs.’
Terese Johansson continues:
‘Drug developers are meeting the treatment demand from the patients and physicians but are the payers willing to pay the price? Drug developers will benefit from being prepared early on to develop strategies to ensure patient access and affordability of their orphan drugs.’
NDA Strategic Advisor and former Chief Exec of the EMA, Dr. Thomas Lˆnngren, as well as the companyís Scientific Director, Dr. Markku Toivonen and the Director of NDAís Regulatory Advisory Board, Prof. Steffen Thirstrup will be present at DIA Europe together with a line-up of experts, and available to discuss these findings. In addition, Hildegard Schmatz, one of NDAís Brexit experts will be available to advice on how to ensure that your company is ëBREXIT-readyí.
NDA staff can be found at booths C 72 and 73 and in the following presentations:
ï Shelley Gandhi & Bill Richardson – Ex MHRA Regulators
(Pre-Conference Short Course) Short Course 3 | Mon, 16th April – 14:00-17:30
Moving from Risk Management to Benefit / Risk Management – Embedding Pharmacovigilance Principles into the product life cycle
ï Beatriz Silva Lima – Non-Clinical Expert DIAlogue 2 – Session 1100 | Tues, 17th April – 14:00-15:30
The New EMA first-in-human (FIH) guideline Part1: Non- Clinical aspects
ï Brian Edwards – Principal Consultant, Pharmacovigilance & Drug Safety
Session 0502 | Wed, 18th April – 14:00-15:15
- Innovative approaches to safety information
- A proposal for a new systems-based approach to medication errors
ï Shelley Gandhi – Strategic Advisor, Pharmacovigilance & Drug Safety
Session 0504 | Thurs, 19th April – 08:30-10:00
Five years on – pharmacovigilance legislation Delivers on long-promised elements
For more about NDAís involvement with the 2018 DIA Europe, visit http://www.ndareg.com/6274-2/
To explore the full Status of New Drug Approvals for 2017 report, visit http://www.ndareg.com/europe-vs-usa-new-drug-product-approvals-in-2017/
About NDA
NDA is an independent consulting group with offices in Stockholm, London, Z¸rich, Munich, Princeton, Boston, San Francisco and Paris. Its mission is to ensure that good medicines reach patients without unnecessary delay. It accomplishes this by providing the pharmaceutical industry with a comprehensive range of professional drug development services focusing on regulatory affairs, health technology assessment, pharmacovigilance and quality assurance. NDAís team of more than 150 full time professionals is comprised of more than 25% ex-regulators from major EU Agencies, and a specialist Advisory Board consisting of Europeís leading regulatory and HTA experts. The NDA Advisory Board provides scientific advice to pharmaceutical companies supporting them in gaining fast and constructive assessment of applications from regulatory agencies and HTA bodies. www.ndareg.com
NDA media contact: anna.perrin@ndareg.com
